Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps
NCT06501807Recruiting
- Sponsor
- CHU de Lille
- Start
- Jul 2024
- Primary completion
- Sep 2034
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of dupilumab, mepolizumab and benralizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by CHU de Lille. Primary endpoint: Comparison of quality of life according to asthmatic status at 5 years. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06501807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501807.